Key facts
- Trefoil Therapeutics’s last known valuation is $59.5M (May 2025).
- It has raised $49.7M across 4 recorded rounds; the latest was Seed Round ($4.6M) in Apr 2025.
- Notable investors include National Institutes of Health, CONNECT(San Diego), Correlation Ventures, Hatteras Venture Partners, FemHealth Ventures — 12 tracked in total.
- Trefoil Therapeutics has filed 5 Form Ds with the SEC since 2016, most recently May 2025 ($4.6M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Trefoil Therapeutics
Funding rounds
4 roundsAbout Trefoil Therapeutics
Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is focused on leveraging its engineered fibroblast growth factor-one protein technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases and help regenerate the endothelial cell layer and eliminate the symptoms associated with this condition that leads to the loss of vision, enabling ophthalmologists to treat patients with severe corneal endothelial diseases and epithelial disorders.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 10
- Website
- trefoiltherapeutics.com/
- Ownership
- Privately Held (backing)
Trefoil Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trefoil Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trefoil Therapeutics in its N-PORT filings yet. We sweep new filings monthly.